Adverse Drug Reactions and Pharmacogenomics
Adverse drug reactions are unintended and harmful responses to medicines given at normal doses, and they account for a substantial share of hospital admissions and inpatient morbidity. Pharmacogenomics studies how inherited variation in genes governing drug metabolism, transport, targets, and immune recognition shapes who develops these reactions, providing a genetic explanation for some reactions that were once considered unpredictable.
Definition
Adverse drug reactions and pharmacogenomics is the study of how genetic variation contributes to harmful, unintended responses to medicines, spanning dose-dependent (Type A) and idiosyncratic or immune-mediated (Type B) reactions and the heritable factors that influence their risk.
Scope
This area orients the reader to the intersection of drug safety and human genetics: the burden and classification of adverse drug reactions, the HLA alleles that predispose to severe immune-mediated reactions, pharmacokinetic and pharmacodynamic gene variants that alter exposure and effect, idiosyncratic reactions, drug-drug interactions modulated by genotype, and the role of chemically reactive metabolites. It is a reference-educational overview of how genetic factors contribute to drug toxicity and is not a guide to prescribing or to individual patient management.
Sub-topics
Core questions
- Which adverse drug reactions have an identifiable genetic basis, and which remain unexplained?
- How do HLA alleles and drug-metabolizing enzyme variants raise the risk of specific reactions?
- When can genetic information meaningfully separate dose-dependent from idiosyncratic toxicity?
- How do reactive metabolites and immune activation connect genotype to clinical harm?
Key concepts
- Type A (dose-dependent) versus Type B (idiosyncratic) adverse reactions
- Pharmacokinetic versus pharmacodynamic genetic variation
- HLA-associated immune-mediated reactions
- Reactive metabolite formation and bioactivation
- Genotype-modulated drug-drug interactions
- Predictive genetic screening and clinical implementation
Mechanisms
Genetic contributions to adverse drug reactions act through several routes. Variants in drug-metabolizing enzymes and transporters change systemic exposure, so that poor metabolisers accumulate parent drug or active metabolites and develop concentration-dependent toxicity, while ultrarapid metabolisers may generate excess active metabolite. Variants in drug targets alter pharmacodynamic sensitivity. A distinct immune route involves human leukocyte antigen alleles that present specific drugs or their metabolites to T cells, triggering severe hypersensitivity. Many serious reactions also depend on bioactivation of a drug to a chemically reactive metabolite that haptenates proteins or causes oxidative stress, linking metabolism, immune recognition, and tissue injury.
Clinical relevance
Adverse drug reactions are a major and partly preventable cause of patient harm, and pharmacogenomic knowledge has reframed several reactions once labelled idiosyncratic as genetically predictable. This area helps readers understand why some patients are at higher genetic risk and how predictive screening evidence is generated and appraised; it describes mechanisms and evidence and is not a substitute for clinical judgement, prescribing decisions, or individualized care.
Epidemiology
Adverse drug reactions are common: a large prospective UK study attributed roughly 1 in 16 hospital admissions to an adverse drug reaction, most judged at least possibly avoidable. The genetically driven severe reactions, such as abacavir hypersensitivity or carbamazepine-induced severe cutaneous reactions, are individually less frequent but carry high morbidity and mortality, and the prevalence of the relevant risk alleles varies markedly across ancestral populations.
Evidence & guidelines
Evidence in this area ranges from prospective cohort estimates of overall adverse-reaction burden to randomized screening trials such as PREDICT-1, which showed that prospective HLA-B*57:01 screening reduced abacavir hypersensitivity. The Clinical Pharmacogenetics Implementation Consortium publishes peer-reviewed guidelines translating verified gene-drug associations into structured recommendations, illustrating how genetic findings move toward practice while remaining outside the scope of individualized advice here.
History
The recognition that some drug reactions are inherited grew out of mid-twentieth-century pharmacogenetics, but the modern fusion with drug safety came with genome-wide and HLA association studies in the 2000s. The identification of HLA-B*57:01 for abacavir hypersensitivity and HLA-B*15:02 for carbamazepine-induced Stevens-Johnson syndrome, followed by the PREDICT-1 screening trial, established that genetic testing could prevent specific severe reactions and catalysed implementation guidelines.
Debates
- How widely should pre-prescription genetic screening be applied?
- Screening is cost-effective and recommended for a few high-impact gene-drug pairs, but extending routine testing to many associations raises questions about predictive value, ancestral allele frequency differences, and implementation cost.
Key figures
- Munir Pirmohamed
- Simon Mallal
- Elizabeth Phillips
- Richard Weinshilboum
Related topics
Seminal works
- pirmohamed-2004
- mallal-2008
- wang-2011
Frequently asked questions
- Are all adverse drug reactions genetic?
- No. Many reactions are dose-dependent or depend on age, organ function, and concurrent medicines. Pharmacogenomics explains a meaningful subset, especially certain severe immune-mediated and metabolism-related reactions, but it is one of several contributing factors.
- How is pharmacogenomics different from pharmacogenetics here?
- Pharmacogenetics traditionally refers to single-gene effects on drug response, while pharmacogenomics takes a genome-wide view; in the context of adverse reactions the terms are often used interchangeably to describe how inherited variation influences drug toxicity.